Rapport Therapeutics (RAPP) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rapport Therapeutics (RAPP) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 10.3% versus a loss of 49.9%. Ultragenyx Pharmaceutical is the larger company by market cap ($1.51 billion vs $1.43 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RAPP | RARE |
|---|---|---|
| Share price | $29.85 | $15.29 |
| Market cap | $1.43B | $1.51B |
| 1-day change | -3.27% | +2.69% |
| YTD return | -1.62% | -35.26% |
| 1-year return | +10.31% | -49.93% |
| 5-year return | — | -81.39% |
| Forward P/E | — | 22.59 |
| EPS (TTM) | $-3.03 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $673.00M |
| Revenue growth (YoY) | — | +20.18% |
| Net income (latest FY) | $-111.48M | $-575.00M |
| Operating margin | — | -79.49% |
| Net margin | — | -85.44% |
| 52-week high | $52.93 | $39.89 |
| 52-week low | $23.75 | $12.73 |
| Distance from 52-week high | -43.60% | -61.67% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +111.19% | +83.45% |
| Average volume | 359.60K | 3.87M |
| Shares outstanding | 47.98M | 98.59M |
| Employees | 84 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RAPP has outperformed RARE by 60.2 percentage points over the past year.
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
RAPP vs RARE FAQ
Which is bigger, Rapport Therapeutics or Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.51B compared with $1.43B for Rapport Therapeutics (RAPP).
Which stock has performed better over the past year, RAPP or RARE?
RAPP returned +10.31% over the past 12 months, compared with -49.93% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Rapport Therapeutics and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.